Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization

  • ACS Med Chem Lett. 2023 Jun 12;14(7):929-935. doi: 10.1021/acsmedchemlett.3c00063.
Louis Chupak  1 ,  Michael Wichroski  1 ,  Xiaofan Zheng  1 ,  Min Ding  1 ,  Scott Martin  1 ,  Christopher Allard  1 ,  Jianliang Shi  2 ,  Robert Gentles  1 ,  Nicholas A Meanwell  2 ,  Jie Fang  2 ,  Daniel Tenney  2 ,  John Tokarski  2 ,  Carolyn Cao  2 ,  Susan Wee  2
Affiliations
  • 1. Bristol Myers Squibb Research and Early Development, 100 Binney Street, Cambridge, Massachusetts 02142, United States.
  • 2. Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543-4000, United States.
PMID: 37465293 DOI: 10.1021/acsmedchemlett.3c00063
Abstract

We describe a phenotypic screening and optimization strategy to discover compounds that block intracellular checkpoint signaling in T-cells. We identified dual DGKα and ζ inhibitors notwithstanding the modest similarity between α and ζ relative to other DGK isoforms. Optimized compounds produced cytokine release and T-cell proliferation consistent with DGK inhibition and potentiated an immune response in human and mouse T-cells. Additionally, lead inhibitor BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program.

Products